A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma

Recent clinical trials have demonstrated targeting PI3K pathway is a promising strategy for the treatment of blood cancers. To identify novel PI3K inhibitors, we performed a high throughput virtual screen and identified several novel small molecule compounds, including PIK-C98 (C98). The cell-free e...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Jingyu, Wang, Man, Yu, Yang, Qi, Huixin, Han, Kunkun, Tang, Juan, Zhang, Zubin, Zeng, Yuanying, Cao, Biyin, Qiao, Chunhua, Zhang, Hongjian, Hou, Tingjun, Mao, Xinliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381587/
https://www.ncbi.nlm.nih.gov/pubmed/25474140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381587/
https://www.ncbi.nlm.nih.gov/pubmed/25474140

Ejemplares similares